Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival
Descripción del Articulo
Se presenta el seguimiento a 8 años de 34 pacientes de edad mayor o igual a 69 años con Linfoma no Hodgkin, incluidos en un estudio de grupos paralelos aleatorios abiertos de fase IIb, para evaluar la efectividad de la amifostina en la prevención de la toxicidad de ciclofosfamida, doxorubicina, vinc...
| Autores: | , , , , , , , , , , , |
|---|---|
| Formato: | artículo |
| Fecha de Publicación: | 2012 |
| Institución: | Seguro Social de Salud |
| Repositorio: | ESSALUD-Institucional |
| Lenguaje: | inglés |
| OAI Identifier: | oai:repositorio.essalud.gob.pe:20.500.12959/461 |
| Enlace del recurso: | https://hdl.handle.net/20.500.12959/461 |
| Nivel de acceso: | acceso abierto |
| Materia: | Oncología Linfoma no Hodgkin Tratamiento Farmacológico Amifostina https://purl.org/pe-repo/ocde/ford#3.05.00 |
| id |
ESSA_51454590021f87f159fd72987a7c0c5e |
|---|---|
| oai_identifier_str |
oai:repositorio.essalud.gob.pe:20.500.12959/461 |
| network_acronym_str |
ESSA |
| network_name_str |
ESSALUD-Institucional |
| repository_id_str |
4277 |
| dc.title.es_PE.fl_str_mv |
Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival |
| title |
Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival |
| spellingShingle |
Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival Gómez, Henry L. Oncología Linfoma no Hodgkin Tratamiento Farmacológico Amifostina https://purl.org/pe-repo/ocde/ford#3.05.00 |
| title_short |
Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival |
| title_full |
Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival |
| title_fullStr |
Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival |
| title_full_unstemmed |
Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival |
| title_sort |
Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival |
| author |
Gómez, Henry L. |
| author_facet |
Gómez, Henry L. Samanéz, César Campana, Frank Neciosup, Silvia P. Vera, Luis Casanova, Luis Leon, Jorge Flores, Claudio Hurtado de Mendoza, Fernando Casteñeda, Carlos A. Pinto, Joseph A. Vallejos, Carlos S. |
| author_role |
author |
| author2 |
Samanéz, César Campana, Frank Neciosup, Silvia P. Vera, Luis Casanova, Luis Leon, Jorge Flores, Claudio Hurtado de Mendoza, Fernando Casteñeda, Carlos A. Pinto, Joseph A. Vallejos, Carlos S. |
| author2_role |
author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Gómez, Henry L. Samanéz, César Campana, Frank Neciosup, Silvia P. Vera, Luis Casanova, Luis Leon, Jorge Flores, Claudio Hurtado de Mendoza, Fernando Casteñeda, Carlos A. Pinto, Joseph A. Vallejos, Carlos S. |
| dc.subject.es_PE.fl_str_mv |
Oncología Linfoma no Hodgkin Tratamiento Farmacológico Amifostina |
| topic |
Oncología Linfoma no Hodgkin Tratamiento Farmacológico Amifostina https://purl.org/pe-repo/ocde/ford#3.05.00 |
| dc.subject.ocde.es_PE.fl_str_mv |
https://purl.org/pe-repo/ocde/ford#3.05.00 |
| description |
Se presenta el seguimiento a 8 años de 34 pacientes de edad mayor o igual a 69 años con Linfoma no Hodgkin, incluidos en un estudio de grupos paralelos aleatorios abiertos de fase IIb, para evaluar la efectividad de la amifostina en la prevención de la toxicidad de ciclofosfamida, doxorubicina, vincristina y prednisona (régimen CHOP). Los pacientes recibieron aleatoriamente CHOP clásico (ciclofosfamida 750 mg/m2, doxorubicina 50 mg/m2, vincristina 1,4 mg / m2 [máximo 2 mg] en el día 1 y prednisona 100 mg/día durante 5 días) o CHOP más amifostina (6 ciclos de amifostina 910 mg / m2 en el día 1). Se evaluó la eficacia (tiempo de progresión, supervivencia libre de enfermedad y sobrevivencia promedio) y parámetros de toxicidad. |
| publishDate |
2012 |
| dc.date.accessioned.none.fl_str_mv |
2019-04-25T16:16:43Z |
| dc.date.available.none.fl_str_mv |
2019-04-25T16:16:43Z |
| dc.date.issued.fl_str_mv |
2012 |
| dc.type.es_PE.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.citation.es_PE.fl_str_mv |
Hematology Oncology Stem Cell Therapy |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.12959/461 |
| identifier_str_mv |
Hematology Oncology Stem Cell Therapy |
| url |
https://hdl.handle.net/20.500.12959/461 |
| dc.language.iso.es_PE.fl_str_mv |
eng |
| language |
eng |
| dc.rights.es_PE.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.uri.es_PE.fl_str_mv |
https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.format.es_PE.fl_str_mv |
application/pdf |
| dc.publisher.es_PE.fl_str_mv |
Seguro Social de Salud (EsSalud) |
| dc.publisher.country.es_PE.fl_str_mv |
PE |
| dc.source.es_PE.fl_str_mv |
Seguro Social de Salud (EsSalud) Repositorio Institucional EsSalud |
| dc.source.none.fl_str_mv |
reponame:ESSALUD-Institucional instname:Seguro Social de Salud instacron:ESSALUD |
| instname_str |
Seguro Social de Salud |
| instacron_str |
ESSALUD |
| institution |
ESSALUD |
| reponame_str |
ESSALUD-Institucional |
| collection |
ESSALUD-Institucional |
| bitstream.url.fl_str_mv |
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/461/1/Addition%20of%20amifostine%20to%20the%20CHOP%20regimen%20in%20elderly%20patients%20with%20aggressive%20non-Hodgkin%20lymphoma%20A%20phase%20II%20trial%20showing%20reduction%20in%20toxicity%20without%20altering%20long-term%20survival.pdf https://repositorio.essalud.gob.pe/bitstream/20.500.12959/461/2/license.txt https://repositorio.essalud.gob.pe/bitstream/20.500.12959/461/3/Addition%20of%20amifostine%20to%20the%20CHOP%20regimen%20in%20elderly%20patients%20with%20aggressive%20non-Hodgkin%20lymphoma%20A%20phase%20II%20trial%20showing%20reduction%20in%20toxicity%20without%20altering%20long-term%20survival.pdf.txt https://repositorio.essalud.gob.pe/bitstream/20.500.12959/461/4/Addition%20of%20amifostine%20to%20the%20CHOP%20regimen%20in%20elderly%20patients%20with%20aggressive%20non-Hodgkin%20lymphoma%20A%20phase%20II%20trial%20showing%20reduction%20in%20toxicity%20without%20altering%20long-term%20survival.pdf.jpg |
| bitstream.checksum.fl_str_mv |
efb9af5070b4d24a808844e5deafe5aa 8a4605be74aa9ea9d79846c1fba20a33 d1bd78f17c3e90a10724d86615a3c7c5 4604b51357c80370ceae322db03b960b |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Seguro Social de Salud – ESSALUD |
| repository.mail.fl_str_mv |
bibliotecacentral@essalud.gob.pe |
| _version_ |
1813537101438779392 |
| spelling |
Gómez, Henry L.Samanéz, CésarCampana, FrankNeciosup, Silvia P.Vera, LuisCasanova, LuisLeon, JorgeFlores, ClaudioHurtado de Mendoza, FernandoCasteñeda, Carlos A.Pinto, Joseph A.Vallejos, Carlos S.2019-04-25T16:16:43Z2019-04-25T16:16:43Z2012Hematology Oncology Stem Cell Therapyhttps://hdl.handle.net/20.500.12959/461Se presenta el seguimiento a 8 años de 34 pacientes de edad mayor o igual a 69 años con Linfoma no Hodgkin, incluidos en un estudio de grupos paralelos aleatorios abiertos de fase IIb, para evaluar la efectividad de la amifostina en la prevención de la toxicidad de ciclofosfamida, doxorubicina, vincristina y prednisona (régimen CHOP). Los pacientes recibieron aleatoriamente CHOP clásico (ciclofosfamida 750 mg/m2, doxorubicina 50 mg/m2, vincristina 1,4 mg / m2 [máximo 2 mg] en el día 1 y prednisona 100 mg/día durante 5 días) o CHOP más amifostina (6 ciclos de amifostina 910 mg / m2 en el día 1). Se evaluó la eficacia (tiempo de progresión, supervivencia libre de enfermedad y sobrevivencia promedio) y parámetros de toxicidad.application/pdfengSeguro Social de Salud (EsSalud)PEinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/4.0/Seguro Social de Salud (EsSalud)Repositorio Institucional EsSaludreponame:ESSALUD-Institucionalinstname:Seguro Social de Saludinstacron:ESSALUDOncologíaLinfoma no HodgkinTratamiento FarmacológicoAmifostinahttps://purl.org/pe-repo/ocde/ford#3.05.00Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survivalinfo:eu-repo/semantics/articleORIGINALAddition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma A phase II trial showing reduction in toxicity without altering long-term survival.pdfAddition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma A phase II trial showing reduction in toxicity without altering long-term survival.pdfapplication/pdf211127https://repositorio.essalud.gob.pe/bitstream/20.500.12959/461/1/Addition%20of%20amifostine%20to%20the%20CHOP%20regimen%20in%20elderly%20patients%20with%20aggressive%20non-Hodgkin%20lymphoma%20A%20phase%20II%20trial%20showing%20reduction%20in%20toxicity%20without%20altering%20long-term%20survival.pdfefb9af5070b4d24a808844e5deafe5aaMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.essalud.gob.pe/bitstream/20.500.12959/461/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52TEXTAddition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma A phase II trial showing reduction in toxicity without altering long-term survival.pdf.txtAddition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma A phase II trial showing reduction in toxicity without altering long-term survival.pdf.txtExtracted texttext/plain18675https://repositorio.essalud.gob.pe/bitstream/20.500.12959/461/3/Addition%20of%20amifostine%20to%20the%20CHOP%20regimen%20in%20elderly%20patients%20with%20aggressive%20non-Hodgkin%20lymphoma%20A%20phase%20II%20trial%20showing%20reduction%20in%20toxicity%20without%20altering%20long-term%20survival.pdf.txtd1bd78f17c3e90a10724d86615a3c7c5MD53THUMBNAILAddition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma A phase II trial showing reduction in toxicity without altering long-term survival.pdf.jpgAddition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma A phase II trial showing reduction in toxicity without altering long-term survival.pdf.jpgGenerated Thumbnailimage/jpeg7192https://repositorio.essalud.gob.pe/bitstream/20.500.12959/461/4/Addition%20of%20amifostine%20to%20the%20CHOP%20regimen%20in%20elderly%20patients%20with%20aggressive%20non-Hodgkin%20lymphoma%20A%20phase%20II%20trial%20showing%20reduction%20in%20toxicity%20without%20altering%20long-term%20survival.pdf.jpg4604b51357c80370ceae322db03b960bMD5420.500.12959/461oai:repositorio.essalud.gob.pe:20.500.12959/4612022-09-09 03:04:19.86Repositorio Seguro Social de Salud – ESSALUDbibliotecacentral@essalud.gob.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 |
| score |
13.905282 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
